OCS — Oculis Holding AG
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953530 ·
Last close
$11.61
Market Cap
$701.11M
52W High
$34.47
52W Low
$10.52
ADV30
981,255
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -21,728,000 | -28,852,000 | 243,993,000 | 64,564,000 | 47,345,000 |
| Dec 2025 | 0 | — | -20,633,000 | -23,514,000 | 235,963,000 | 81,329,000 | 39,893,000 |
| Sep 2025 | 0 | — | -20,296,000 | -16,855,000 | 167,836,000 | 46,440,000 | 37,242,000 |
| Jun 2025 | 0 | — | -20,768,000 | -25,375,000 | 181,621,000 | 64,265,000 | 38,525,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,304,000
Investing CF
$-60,934,000
Financing CF
$186,918,000
CapEx
$-1,388,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-384,514,000
Inventory
—
Receivables
$1,794,000
ST Investments
$131,684,000
EBIT TTM
$-98,310,000
Pretax Income TTM
$-99,143,000
Interest Exp TTM
$833,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,123,000
EBITDA
$-83,243,000
Free Cash Flow
$-27,761,624
Enterprise Value
$481,319,520
Total Cash
$222,034,000
Total Debt
$2,248,000
Shares Out
60,388,073
Trailing EPS
$-2.12
Book Value
$4.07
ROE
-52.7%
ROA
-23.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,672,000 | -98,957,000 | 235,963,000 | 39,893,000 | — | -66,304,000 |
| Dec 2024 | 0 | -73,204,000 | -85,777,000 | 120,353,000 | 46,970,000 | — | -48,919,000 |
| Dec 2023 | 0 | -45,851,000 | -88,802,000 | 114,353,000 | 20,625,000 | — | -55,037,000 |
| Dec 2022 | 0 | -32,376,000 | -38,698,000 | 37,060,000 | 135,051,000 | — | -25,074,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.06
Max Pain — expiry 2026-06-18
max pain strike: $22.50 · spot: $11.34 · call oi: 390 · put oi: 1,014
Expected Move to 2026-06-18:
±$1.33
(11.68%) —
implied range
$10.02 –
$12.67
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | $695.77M | $11.14 | — |
| SMNR | Semnur Pharmaceuticals, Inc. | $690.63M | $3.00 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $680.10M | $32.28 | — |
| OMER | OMEROS CORP | $675.26M | $9.33 | — |
| CRMD | CorMedix Inc. | $673.90M | $8.59 | — |
News headlines (Yahoo Finance, 1h cache)
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
2026-06-11 08:00 · Yahoo
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
2026-06-09 08:00 · Yahoo
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
2026-06-08 19:25 · Yahoo
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
2026-06-08 11:16 · Yahoo
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
2026-05-31 21:03 · Yahoo
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target
2026-05-29 20:18 · Yahoo
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
2026-05-29 19:46 · Yahoo
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
2026-05-29 19:06 · Yahoo
Etsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls
2026-05-21 13:40 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-05-15 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.